Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 07:06 am EDT

Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year


Presentation of study design for potentially...

Related Keywords

United Kingdom ,Seika ,Kyongsang Bukto ,South Korea ,India ,Sri Lanka ,Switzerland ,Japan ,United Arab Emirates ,Milan ,Lombardia ,Italy ,Bresso ,Israel ,United States ,Canada ,Australia ,America ,Swiss , ,Dusseldorf Stock Exchange ,Newron Pharmaceuticals ,Supernus Pharmaceuticals ,Schizophrenia International Research Society ,Swiss Exchange ,European Union ,Negative Syndrome Scale ,Clinical Global Impression ,Strauss Carpenter Level ,Latin America ,Meiji Seika ,